Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies.

Miller NA, Reddy MB, Heikkinen AT, Lukacova V, Parrott N.

Clin Pharmacokinet. 2019 Feb 7. doi: 10.1007/s40262-019-00741-9. [Epub ahead of print] Review.

PMID:
30729397
2.

PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective.

Stillhart C, Pepin X, Tistaert C, Good D, Van Den Bergh A, Parrott N, Kesisoglou F.

AAPS J. 2019 Jan 23;21(2):19. doi: 10.1208/s12248-019-0292-3.

PMID:
30673891
3.

Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry.

Badée J, Qiu N, Parrott N, Collier AC, Schmidt S, Fowler S.

Drug Metab Dispos. 2019 Feb;47(2):124-134. doi: 10.1124/dmd.118.084301. Epub 2018 Nov 26.

PMID:
30478159
4.

Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children.

Johnson TN, Cleary Y, Parrott N, Reigner B, Smith JR, Toovey S.

Br J Clin Pharmacol. 2019 Jan;85(1):100-113. doi: 10.1111/bcp.13764. Epub 2018 Nov 5.

PMID:
30198595
5.

In Vivo Predictive Dissolution and Simulation Workshop Report: Facilitating the Development of Oral Drug Formulation and the Prediction of Oral Bioperformance.

Tsume Y, Patel S, Fotaki N, Bergstrӧm C, Amidon GL, Brasseur JG, Mudie DM, Sun D, Bermejo M, Gao P, Zhu W, Sperry DC, Vertzoni M, Parrott N, Lionberger R, Kambayashi A, Hermans A, Lu X, Amidon GE.

AAPS J. 2018 Sep 6;20(6):100. doi: 10.1208/s12248-018-0260-3. No abstract available.

PMID:
30191341
6.

Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches.

Guo Y, Chu X, Parrott NJ, Brouwer KLR, Hsu V, Nagar S, Matsson P, Sharma P, Snoeys J, Sugiyama Y, Tatosian D, Unadkat JD, Huang SM, Galetin A; International Transporter Consortium.

Clin Pharmacol Ther. 2018 Nov;104(5):865-889. doi: 10.1002/cpt.1183. Epub 2018 Sep 12.

PMID:
30059145
7.

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib.

Morcos PN, Cleary Y, Sturm-Pellanda C, Guerini E, Abt M, Donzelli M, Vazvaei F, Balas B, Parrott N, Yu L.

J Clin Pharmacol. 2018 Dec;58(12):1618-1628. doi: 10.1002/jcph.1286. Epub 2018 Jul 27.

8.

Importance of target-mediated drug disposition for small molecules.

Smith DA, van Waterschoot RAB, Parrott NJ, Olivares-Morales A, Lavé T, Rowland M.

Drug Discov Today. 2018 Dec;23(12):2023-2030. doi: 10.1016/j.drudis.2018.06.010. Epub 2018 Jun 19. Review.

PMID:
29928850
9.

Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies.

Tistaert C, Heimbach T, Xia B, Parrott N, Samant TS, Kesisoglou F.

J Pharm Sci. 2019 Jan;108(1):592-602. doi: 10.1016/j.xphs.2018.05.024. Epub 2018 Jun 12.

PMID:
29906472
10.

The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling.

Badée J, Fowler S, de Wildt SN, Collier AC, Schmidt S, Parrott N.

Clin Pharmacokinet. 2019 Feb;58(2):189-211. doi: 10.1007/s40262-018-0681-2. Review.

PMID:
29862468
11.

Impact of target interactions on small-molecule drug disposition: an overlooked area.

van Waterschoot RAB, Parrott NJ, Olivares-Morales A, Lavé T, Rowland M, Smith DA.

Nat Rev Drug Discov. 2018 Apr;17(4):299. doi: 10.1038/nrd.2018.26. Epub 2018 Feb 23. No abstract available.

PMID:
29472637
12.

Simultaneous Assessment of Clearance, Metabolism, Induction, and Drug-Drug Interaction Potential Using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor.

Kratochwil NA, Triyatni M, Mueller MB, Klammers F, Leonard B, Turley D, Schmaler J, Ekiciler A, Molitor B, Walter I, Gonsard PA, Tournillac CA, Durrwell A, Marschmann M, Jones R, Ullah M, Boess F, Ottaviani G, Jin Y, Parrott NJ, Fowler S.

J Pharmacol Exp Ther. 2018 May;365(2):237-248. doi: 10.1124/jpet.117.245712. Epub 2018 Feb 16.

PMID:
29453199
13.

Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.

Cleary Y, Gertz M, Morcos PN, Yu L, Youdim K, Phipps A, Fowler S, Parrott N.

Clin Pharmacol Ther. 2018 Sep;104(3):505-514. doi: 10.1002/cpt.956. Epub 2017 Dec 27.

PMID:
29226313
14.

A novel orally available small molecule that inhibits hepatitis B virus expression.

Mueller H, Wildum S, Luangsay S, Walther J, Lopez A, Tropberger P, Ottaviani G, Lu W, Parrott NJ, Zhang JD, Schmucki R, Racek T, Hoflack JC, Kueng E, Point F, Zhou X, Steiner G, Lütgehetmann M, Rapp G, Volz T, Dandri M, Yang S, Young JAT, Javanbakht H.

J Hepatol. 2018 Mar;68(3):412-420. doi: 10.1016/j.jhep.2017.10.014. Epub 2017 Oct 25.

15.

Investigating Oral Absorption of Carbamazepine in Pediatric Populations.

Kohlmann P, Stillhart C, Kuentz M, Parrott N.

AAPS J. 2017 Nov;19(6):1864-1877. doi: 10.1208/s12248-017-0149-6. Epub 2017 Oct 2.

PMID:
28971365
16.

The great barrier belief: The blood-brain barrier and considerations for juvenile toxicity studies.

Schmitt G, Parrott N, Prinssen E, Barrow P.

Reprod Toxicol. 2017 Sep;72:129-135. doi: 10.1016/j.reprotox.2017.06.043. Epub 2017 Jun 13. Review.

PMID:
28627392
17.

Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities.

Fowler S, Morcos PN, Cleary Y, Martin-Facklam M, Parrott N, Gertz M, Yu L.

Curr Pharmacol Rep. 2017;3(1):36-49. doi: 10.1007/s40495-017-0082-5. Epub 2017 Feb 1. Review.

18.

Characterising Drug Release from Immediate-Release Formulations of a Poorly Soluble Compound, Basmisanil, Through Absorption Modelling and Dissolution Testing.

Stillhart C, Parrott NJ, Lindenberg M, Chalus P, Bentley D, Szepes A.

AAPS J. 2017 May;19(3):827-836. doi: 10.1208/s12248-017-0060-1. Epub 2017 Feb 24.

PMID:
28236228
19.

Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects Modeling.

Kratochwil NA, Meille C, Fowler S, Klammers F, Ekiciler A, Molitor B, Simon S, Walter I, McGinnis C, Walther J, Leonard B, Triyatni M, Javanbakht H, Funk C, Schuler F, Lavé T, Parrott NJ.

AAPS J. 2017 Mar;19(2):534-550. doi: 10.1208/s12248-016-0019-7. Epub 2017 Jan 3.

PMID:
28050713
20.

Quantitative systems pharmacology: a promising approach for translational pharmacology.

Gadkar K, Kirouac D, Parrott N, Ramanujan S.

Drug Discov Today Technol. 2016 Sep - Dec;21-22:57-65. doi: 10.1016/j.ddtec.2016.11.001. Epub 2016 Nov 24. Review.

PMID:
27978989
21.

Translational PK/PD modeling to increase probability of success in drug discovery and early development.

Lavé T, Caruso A, Parrott N, Walz A.

Drug Discov Today Technol. 2016 Sep - Dec;21-22:27-34. doi: 10.1016/j.ddtec.2016.11.005. Epub 2016 Dec 10. Review.

PMID:
27978984
22.

Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction Metabolized.

Fowler S, Guerini E, Qiu N, Cleary Y, Parrott N, Greig G, Mallalieu NL.

J Pharmacol Exp Ther. 2017 Jan;360(1):164-173. Epub 2016 Nov 7.

PMID:
27821711
23.

Physiologically Based Absorption Modeling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Alectinib.

Parrott NJ, Yu LJ, Takano R, Nakamura M, Morcos PN.

AAPS J. 2016 Nov;18(6):1464-1474. Epub 2016 Jul 22.

PMID:
27450228
24.

A Physiologically Based Pharmacokinetic Model for Ganciclovir and Its Prodrug Valganciclovir in Adults and Children.

Lukacova V, Goelzer P, Reddy M, Greig G, Reigner B, Parrott N.

AAPS J. 2016 Nov;18(6):1453-1463. Epub 2016 Jul 22.

PMID:
27450227
25.

Erratum to: Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach.

Lignet F, Sherbetjian E, Kratochwil N, Jones R, Suenderhauf C, Otteneder MB, Singer T, Parrott N.

Pharm Res. 2016 Nov;33(11):2844. No abstract available.

PMID:
27549317
26.

Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects.

Morcos PN, Parrott N, Banken L, Timpe C, Lindenberg M, Guerini E, Dall G, Bogman K, Sturm C, Zeaiter A, Martin-Facklam M, Phipps A.

Clin Pharmacol Drug Dev. 2017 May;6(3):266-279. doi: 10.1002/cpdd.299. Epub 2016 Oct 3.

PMID:
27545871
27.

Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects.

Morcos PN, Guerini E, Parrott N, Dall G, Blotner S, Bogman K, Sturm C, Balas B, Martin-Facklam M, Phipps A.

Clin Pharmacol Drug Dev. 2017 Jul;6(4):388-397. doi: 10.1002/cpdd.296. Epub 2016 Sep 28.

PMID:
27545320
28.

Bottom-up Meets Top-down: Complementary Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling for Regulatory Approval of a Dosing Algorithm of Valganciclovir in Very Young Children.

Jorga K, Chavanne C, Frey N, Lave T, Lukacova V, Parrott N, Peck R, Reigner B.

Clin Pharmacol Ther. 2016 Dec;100(6):761-769. doi: 10.1002/cpt.449. Epub 2016 Sep 29.

PMID:
27530217
29.

Well, I Wouldn't be Any Worse Off, Would I, Than I am Now? A Qualitative Study of Decision-Making, Hopes, and Realities of Adults With Type 1 Diabetes Undergoing Islet Cell Transplantation.

Speight J, Woodcock AJ, Reaney MD, Amiel SA, Johnson P, Parrott N, Rutter MK, Senior P, Shaw JA.

Transplant Direct. 2016 Apr 21;2(5):e72. doi: 10.1097/TXD.0000000000000581. eCollection 2016 May.

30.

Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach.

Lignet F, Sherbetjian E, Kratochwil N, Jones R, Suenderhauf C, Otteneder MB, Singer T, Parrott N.

Pharm Res. 2016 Oct;33(10):2565-79. doi: 10.1007/s11095-016-1982-5. Epub 2016 Jul 28. Erratum in: Pharm Res. 2016 Nov;33(11):2844.

PMID:
27469324
31.

Preclinical Reproductive and Developmental Toxicity Profile of a Glycine Transporter Type 1 (Glyt1) Inhibitor.

Barrow P, Parrott N, Alberati D, Paehler A, Koerner A.

Birth Defects Res B Dev Reprod Toxicol. 2016 Jun;107(3):148-56. doi: 10.1002/bdrb.21179. Epub 2016 May 24.

PMID:
27221585
32.

Using Physiologically Based Pharmacokinetic (PBPK) Modelling to Gain Insights into the Effect of Physiological Factors on Oral Absorption in Paediatric Populations.

Villiger A, Stillhart C, Parrott N, Kuentz M.

AAPS J. 2016 Jul;18(4):933-47. doi: 10.1208/s12248-016-9896-z. Epub 2016 Apr 8.

PMID:
27060007
33.

Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs.

Kristoffersson AN, David-Pierson P, Parrott NJ, Kuhlmann O, Lave T, Friberg LE, Nielsen EI.

Pharm Res. 2016 May;33(5):1115-25. doi: 10.1007/s11095-016-1856-x. Epub 2016 Jan 19.

PMID:
26786016
34.

Combining 'Bottom-Up' and 'Top-Down' Methods to Assess Ethnic Difference in Clearance: Bitopertin as an Example.

Feng S, Shi J, Parrott N, Hu P, Weber C, Martin-Facklam M, Saito T, Peck R.

Clin Pharmacokinet. 2016 Jul;55(7):823-832. doi: 10.1007/s40262-015-0356-1.

35.

Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans.

Glenn KJ, Yu LJ, Reddy MB, Fretland AJ, Parrott N, Hussain S, Palacios M, Vazvaei F, Zhi J, Tuerck D.

Xenobiotica. 2016 Aug;46(8):667-76. doi: 10.3109/00498254.2015.1110761. Epub 2015 Nov 19.

PMID:
26586447
36.

Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.

Boetsch C, Parrott N, Fowler S, Poirier A, Hainzl D, Banken L, Martin-Facklam M, Hofmann C.

Clin Pharmacokinet. 2016 Feb;55(2):237-47. doi: 10.1007/s40262-015-0312-0.

PMID:
26341813
37.

Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway.

Feng S, Cleary Y, Parrott N, Hu P, Weber C, Wang Y, Yin OQ, Shi J.

Eur J Clin Pharmacol. 2015 May;71(5):617-24. doi: 10.1007/s00228-015-1834-y. Epub 2015 Mar 24.

PMID:
25801493
38.

The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.

Heikkinen AT, Lignet F, Cutler P, Parrott N.

Proteomics Clin Appl. 2015 Aug;9(7-8):732-44. doi: 10.1002/prca.201400147. Epub 2015 Apr 13. Review.

PMID:
25676057
39.

Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.

Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, Snoeys J, Upreti VV, Zheng M, Hall SD.

Clin Pharmacol Ther. 2015 Mar;97(3):247-62. doi: 10.1002/cpt.37. Epub 2015 Jan 9. Review.

PMID:
25670209
40.

Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression.

Lindemann L, Porter RH, Scharf SH, Kuennecke B, Bruns A, von Kienlin M, Harrison AC, Paehler A, Funk C, Gloge A, Schneider M, Parrott NJ, Polonchuk L, Niederhauser U, Morairty SR, Kilduff TS, Vieira E, Kolczewski S, Wichmann J, Hartung T, Honer M, Borroni E, Moreau JL, Prinssen E, Spooren W, Wettstein JG, Jaeschke G.

J Pharmacol Exp Ther. 2015 Apr;353(1):213-33. doi: 10.1124/jpet.114.222463. Epub 2015 Feb 9.

PMID:
25665805
41.

Quantitative ADME proteomics - CYP and UGT enzymes in the Beagle dog liver and intestine.

Heikkinen AT, Friedlein A, Matondo M, Hatley OJ, Petsalo A, Juvonen R, Galetin A, Rostami-Hodjegan A, Aebersold R, Lamerz J, Dunkley T, Cutler P, Parrott N.

Pharm Res. 2015 Jan;32(1):74-90. doi: 10.1007/s11095-014-1446-8. Epub 2014 Jul 18.

PMID:
25033762
42.

Physiologically based absorption modelling to predict the impact of drug properties on pharmacokinetics of bitopertin.

Parrott N, Hainzl D, Scheubel E, Krimmer S, Boetsch C, Guerini E, Martin-Facklam M.

AAPS J. 2014 Sep;16(5):1077-84. doi: 10.1208/s12248-014-9639-y. Epub 2014 Jun 27.

43.

Pharmacokinetics of paracetamol in Göttingen minipigs: in vivo studies and modeling to elucidate physiological determinants of absorption.

Suenderhauf C, Tuffin G, Lorentsen H, Grimm HP, Flament C, Parrott N.

Pharm Res. 2014 Oct;31(10):2696-707. doi: 10.1007/s11095-014-1367-6. Epub 2014 May 3.

PMID:
24792825
44.

Use of Pre-Ablation Radioiodine-131 Scan to Assess the Impact of Surgical Volume and Specialisation following Thyroidectomy for Differentiated Thyroid Carcinoma.

Yap BK, Homer J, Parrott N, Loughran S, Murby B, Swindell R, Gandhi A.

Eur Thyroid J. 2013 Dec;2(4):275-81. doi: 10.1159/000355911. Epub 2013 Nov 20.

45.

Applications of a 7-day Caco-2 cell model in drug discovery and development.

Peng Y, Yadava P, Heikkinen AT, Parrott N, Railkar A.

Eur J Pharm Sci. 2014 Jun 2;56:120-30. doi: 10.1016/j.ejps.2014.02.008. Epub 2014 Feb 24.

PMID:
24576578
46.

Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.

Baneyx G, Parrott N, Meille C, Iliadis A, Lavé T.

Eur J Pharm Sci. 2014 Jun 2;56:1-15. doi: 10.1016/j.ejps.2014.02.002. Epub 2014 Feb 12.

PMID:
24530864
47.

Biorelevant media for transport experiments in the Caco-2 model to evaluate drug absorption in the fasted and the fed state and their usefulness.

Markopoulos C, Thoenen F, Preisig D, Symillides M, Vertzoni M, Parrott N, Reppas C, Imanidis G.

Eur J Pharm Biopharm. 2014 Apr;86(3):438-48. doi: 10.1016/j.ejpb.2013.10.017. Epub 2013 Oct 31.

PMID:
24184673
48.

Attainment of metabolic goals in the integrated UK islet transplant program with locally isolated and transported preparations.

Brooks AM, Walker N, Aldibbiat A, Hughes S, Jones G, de Havilland J, Choudhary P, Huang GC, Parrott N, McGowan NW, Casey J, Mumford L, Barker P, Burling K, Hovorka R, Walker M, Smith RM, Forbes S, Rutter MK, Amiel S, Rosenthal MJ, Johnson P, Shaw JA.

Am J Transplant. 2013 Dec;13(12):3236-43. doi: 10.1111/ajt.12469. Epub 2013 Oct 1.

49.

An unusual cause of persistent postpartum vaginal discharge.

Parrott N, Asensio M, Gupta NK.

Int J STD AIDS. 2013 Oct;24(10):840-1. doi: 10.1177/0956462413487329. Epub 2013 Jul 16.

PMID:
23970614
50.

In vitro and ex vivo investigation of the impact of luminal lipid phases on passive permeability of lipophilic small molecules using PAMPA.

Markopoulos C, Imanidis G, Vertzoni M, Symillides M, Parrott N, Reppas C.

Pharm Res. 2013 Dec;30(12):3145-53. doi: 10.1007/s11095-013-1141-1. Epub 2013 Jul 27.

PMID:
23893021

Supplemental Content

Loading ...
Support Center